Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 616-621

  Goren, Marshall P ^a   Anthony, Lowell B ^a   Hande, Kenneth R ^a   Johnson, David H ^a   Brade, Wolfgang P ^a   Frazier, Mark W ^a   Bush, Dorothy A ^a   Li, Jackie T ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG UPTAKE; DRUG URINE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031896243     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.616     Document Type: Article

References (10)

1. Brock N, Pohl J, Stekar J, et al: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377-1387, 1982
2. Fukuoka M, Negoro S, Masuda N, et al: Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117:473-478, 1991
3. Goren MP: Oral administration of mesna with ifosfamide. Semin Oncol 23:91-96, 1996 (suppl 6)
4. Goren MP, McKenna LM, Goodman TL: Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother Pharmacol 40:371-375, 1997
5. James CA, Mant TG, Rogers HJ: Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 23:561-568, 1987
6. Crawhall JC, Kalant D: Measurement of biological disulfides by postcolumn sulfitolysis following separation by HPLC. Anal Biochem 172:479-483, 1988
7. Goren MP, Pratt CB, Meyer WM, et al: Mesna excretion and ifosfamide nephrotoxicity in children. Cancer Res 49:7153-7157, 1989
8. Stofer-Vogel B, Cerny T, Borner M, et al: Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol 32:78-81, 1993
9. Jones MS, Murrell RD, Shaw IC: Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 21:553-555, 1985
10. Burkert H, Lucker PW, Wetzelsberger N, et al: Bioavailability of orally administered mesna. Arzneimittelforschung 34:1597-1600, 1984